Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 3/20 | 0.57 |
| ▸ | SNCA | P37840 | 4/20 | 0.52 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18010072 | 0.88 | TOP1 (0.57) | TOP1SNCATOP2ATOP2BMEN1 | |
| SCHEMBL16692656 | 0.83 | TOP1 (0.74) | TOP1SNCATOP2ATOP2BMEN1 | |
| SCHEMBL18993382 | 0.82 | TOP1 (0.60) | TOP1SNCATOP2ATOP2BMEN1 | |
| SCHEMBL18027778 | 0.82 | NPC1 (0.64) | TOP1SNCATOP2ATOP2BKCNQ3 | |
| SCHEMBL18010194 | 0.81 | AURKB (0.61) | TOP1MEN1KMT2A | |
| SCHEMBL18010105 | 0.78 | NQO2 (0.69) | TOP1SNCATOP2ATOP2BMEN1 | |
| SCHEMBL18010146 | 0.78 | TOP1 (0.48) | TOP1SNCATOP2ATOP2BMEN1 | |
| SCHEMBL18010045 | 0.78 | MEN1 (0.59) | SNCAMEN1KMT2A | |
| SCHEMBL16692727 | 0.75 | NPC1 (0.47) | MEN1KMT2AKCNQ3KCNQ2 | |
| SCHEMBL16692725 | 0.75 | POLB (0.73) | SNCAMEN1KMT2APTPN1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | claimed |
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9682931-B2 | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof | UBE INDUSTRIES, LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-3064489-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | Ube Industries, Ltd. (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | UBE INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244407-A1 | ARYLOYL(OXY OR AMINO)PENTAFLUOROSULFANYLBENZENE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PRODRUGS THEREOF | SLCO1B1, SLCO2B1, SLCO1B3 | TOP1 4791/4885SNCA 1648/4885TOP2A 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.